Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088765 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL31553097 | 0.78 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL789665 | 0.75 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL23218588 | 0.71 | ALOX15 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL3464570 | 0.71 | AHR (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL16844564 | 0.71 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL21625583 | 0.68 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL21625594 | 0.67 | PTPN1 (0.37) | — | |
| SCHEMBL21625587 | 0.67 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL31333134 | 0.67 | HTR2A (0.33) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| CN-115515679-A | Heterocyclic amides and their use for modulating splicing | 雷密克斯医疗公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | HTR2A 2930/4885HTR2C 3547/4885HTR2B 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.